A randomised trial of high dose therapy and autologous bone marrow transplantation versus continuing conventional combination chemotherapy for adults with lymphoblastic lymphoma

Submission date	Recruitment status No longer recruiting	Prospectively registered		
01/07/2001		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
01/07/2001	Completed	[X] Results		
Last Edited	Condition category	Individual participant data		
28/11/2019	Cancer			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Мг--

Contact details

UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

Additional identifiers

Protocol serial number LY01

Study information

Scientific Title

A randomised trial of high dose therapy and autologous bone marrow transplantation versus continuing conventional combination chemotherapy for adults with lymphoblastic lymphoma

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Lymphoma (non-Hodgkin's) cancer

Interventions

All patients receive induction therapy and conventional chemotherapy regimens. Patients achieving complete remission or partial remission are randomised to either:

- 1. Regimen A: Continue therapy on conventional regimen. The recommended conventional regimen is modified LSA2L2.
- 2. Regimen B: High dose therapy and ABMT.

Intervention Type

Drug

Phase

Not Applicable

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s))

Not provided at time of registration

Completion date

30/04/1997

Eligibility

Key inclusion criteria

- 1. Histologically documented lymphoblastic lymphoma
- 2. No prior chemotherapy or radiotherapy, except chemotherapy given for immediate relief of symptoms at presentation
- 3. Age 15 or over
- 4. All stages
- 5. No circulating blasts
- 6. Normal values for renal and hepatic function, unless directly attributable to lymphoma
- 7. Normal cardiac function
- 8. No evidence of Human Immunodeficiency Virus (HIV) infection

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

119

Key exclusion criteria

Patients will be excluded if they have HLA-identical siblings who are undergoing allogenic bone marrow transplantation. These patients should be registered with the trials office but will not be randomised.

Date of first enrolment

01/01/1992

Date of final enrolment

30/04/1997

Locations

Countries of recruitment

United Kingdom

England

Study participating centre MRC Clinical Trials Unit London United Kingdom

NW1 2DA

Sponsor information

Organisation

Cancer Research UK (CRUK) (UK)

ROR

https://ror.org/054225q67

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added Peer reviewed?	Patient-facing
Results article	results	01/06/2001	28/11/2019 Yes	No
	5			

Participant information sheet 11/11/2025 No Yes